- Previous Close
0.1684 - Open
0.1514 - Bid 0.1564 x --
- Ask 0.1792 x --
- Day's Range
0.1514 - 0.1514 - 52 Week Range
0.1120 - 0.5980 - Volume
11,248 - Avg. Volume
410,426 - Market Cap (intraday)
23.231M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.60
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden.
www.lipigon.seRecent News: LPGO.ST
View MorePerformance Overview: LPGO.ST
Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LPGO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LPGO.ST
View MoreValuation Measures
Market Cap
24.98M
Enterprise Value
14.24M
Trailing P/E
3.77
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.02
Price/Book (mrq)
1.35
Enterprise Value/Revenue
1.59
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-217.19%
Return on Assets (ttm)
-41.80%
Return on Equity (ttm)
-76.68%
Revenue (ttm)
9.33M
Net Income Avi to Common (ttm)
-20.25M
Diluted EPS (ttm)
-0.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
19.48M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.2M